| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editorial |
From the Section of Endocrinology, Diabetes, and Metabolism, Temple University School of Medicine, Philadelphia, Pa.
Correspondence to Kevin Jon Williams, MD, Section of Endocrinology, Diabetes and Metabolism, Temple University School of Medicine, 3322 North Broad Street, Medical Office Building, Room 212, Philadelphia, PA 19140. E-mail K_Williams{at}mail.jci.tju.edu
The recent discovery of a dysfunctional mutation of GPIHBP1 in a man with chylomicronemia implicates this protein in human physiology. GPIHBP1 can be placed in the larger context of other molecular participants in chylomicron docking and hydrolysis on microvascular endothelium, caloric delivery, and remnant lipoprotein generation. Critical questions include the regulation—and dysregulation—of these processes in states of overnutrition, underexertion, obesity, insulin resistance, and diabetes.
Related Article:
Arterioscler Thromb Vasc Biol 2009 29: 956-962.
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |